


Data Sheet

Product Name:	AGL-2263
Cat. No.:	CS-0062886
CAS No.:	638213-98-6
Molecular Formula:	C ₁₇ H ₁₀ N ₂ O ₅
Molecular Weight:	322.27
Target:	Insulin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Solubility:	DMSO : 125 mg/mL (387.87 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

AGL-2263 is an **insulin receptor (IR)** blocker. IC₅₀ & Target: Insulin receptor^[1]. **In Vitro:** AGL-2263 is an insulin receptor (IR) blocker^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[1]**Trophoblast cells** are prepared from normal or GDM placentas. They are incubated in the presence of stimulants, insulin (100 nM) or both insulin and **AGL-2263 (AGL, 5 μM)** IR blocker, together for 24 hr^[1].

References:

[1]. Li Y, et al. GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5697-705.

CAIndexNames:

Benzenepropanenitrile, α-[(2,3-dihydro-2-oxo-5-benzoxazolyl)methylene]-3,4-dihydroxy-β-oxo-, (αE)-

SMILES:

O=C(C1=CC(O)=C(O)C=C1)/C(C#N)=C/C2=CC=C(OC3=O)C(N3)=C2

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA